What Happened?
San Mateo, CA-based Sagimet Resigned Dennis Hom as Chief Financial Officer and Head Corporate Development
About the Company
Sagimet Biosciences is a clinical-stage biopharmaceutical company focused on developing novel therapeutics to treat important diseases such as the liver disease NASH and specific cancers, with focus on targeting dysfunctional metabolic pathways. The company has unique expertise in FASN biology and has created a platform of proprietary FASN inhibitors.
About the Person
Dennis Hom is Chief Financial Officer and Head Corporate Development at Sagimet. Previously, Dennis held various senior HR leadership roles in the industry.
Info Source
Press Release
Short Profile